Half-Year 2022 Financial and Clinical Trials Update
Upcoming launch of ElecsysⓇ IGRA SARS-CoV-2
Improving the understanding of immunity against SARS-CoV-2
Step1
T-Cell Stimulation
Testing workflow
Positive
Control
Negative
SARS-COV-2
Control specific tube
Roche
Step 2
Quantification of IFN-Y
(on Roche IA instrument)
•
Detects T-cell mediated immune response by measuring IFN-y
release upon stimulation with 189 SARS-CoV-2 specific
antigens, indicative of past exposure or vaccination
Complements SARS-CoV-2 antibody tests to better
understand host response and protective immunity
May support risk stratification for progression to severe
disease and/or protection
Positive control: Mitogen stimulus, controls for sample quality and T-cell fitness
Negative control: no stimulus, controls for baseline IFN-y level
SARS-CoV-2 specific tube: contains SARS-CoV-2 specific antigens in coating, stimulates Anti-
SARS-COV-2 T-Cell response
Quality control passed ? SARS-CoV-2 specific IFN-y response, determines reactivity
IA-Immunoassay; IFN-Y-Interferon gamma; IGRA=Interferon gamma release assay
40
40View entire presentation